Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – FitzGerald Website

David J. FitzGerald, Ph.D.

Selected Publications

1)  Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ.
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.
J. Biol. Chem. 265: 20678-85, 1990.
[Journal]
2)  FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, Winkles JA, Strickland D, Leppla S.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
J. Cell Biol. 129: 1533-41, 1995.
[Journal]
3)  Mansfield E, Amlot P, Pastan I, FitzGerald DJ.
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Blood. 90: 2020-6, 1997.
[Journal]
4)  Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, Fitzgerald DJ.
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Mol. Cancer Ther. 9: 2007-15, 2010.
[Journal]
5)  Antignani A, Sarnovsky R, Fitzgerald DJ.
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including Pseudomonas exotoxin.
Mol. Cancer Ther. 13: 1655-63, 2014.
[Journal]
6)  Liu XF, Xiang L, FitzGerald DJ, Pastan I.
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Mol. Cancer Ther. 13: 82-9, 2014.
[Journal]
7)  Hollevoet K, Antignani A, Fitzgerald DJ, Pastan I.
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
J. Immunother. 37: 8-15, 2014.
[Journal]
8)  Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.
Immunotoxins for leukemia.
Blood. 123: 2470-7, 2014.
[Journal]
9)  Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O' Shea JJ, Pastan IH, FitzGerald DJ.
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts.
J. Immunol. [Epub ahead of print], 2014.
[Journal]
10)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
[Journal]
11)  Liu XF, Fitzgerald DJ, Pastan I.
The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin.
Cancer Res. 73: 2281-8, 2013.
[Journal]
12)  Mattoo A, Fitzgerald DJ.
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant Small Cell Lung Cancer cell lines.
Int J Cancer. 132: 978-87, 2012.
[Journal]
13)  Wei H, Xiang L, Wayne AS, Chertov O, Fitzgerald DJ, Bera TK, Pastan I.
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Proc. Natl. Acad. Sci. U.S.A. 109: 6898-903, 2012.
[Journal]
14)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
[Journal]
15)  Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I.
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Leuk. Lymphoma. 52 Suppl 2: 79-81, 2011.
[Journal]
16)  Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
Immunotoxins with decreased immunogenicity and improved activity.
Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011.
[Journal]
17)  Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011.
[Journal]
18)  FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I.
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Cancer Res. 71: 6300-9, 2011.
[Journal]
19)  Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I.
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Clin. Cancer Res. 16: 1894-903, 2010.
[Journal]
20)  Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R, Zhang J, Hassan R, FitzGerald DJ.
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Cancer Immunol. Immunother. 59: 737-46, 2010.
[Journal]
21)  Du X, Youle RJ, FitzGerald DJ, Pastan I.
Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1.
Mol. Cell. Biol. 30: 3444-52, 2010.
[Journal]
22)  Sharma AK, FitzGerald D.
Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.
Toxicon. 56: 1025-34, 2010.
[Journal]
23)  Sharma AK, FitzGerald D.
Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.
Toxicon. 56: 1025-34, 2010.
[Journal]
24)  Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I.
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Blood. 113: 3792-800, 2009.
[Journal]
25)  Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I.
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J. Clin. Oncol. 27: 2983-90, 2009.
[Journal]
26)  Sarnovsky R, Rea J, Makowski M, Hertle R, Kelly C, Antignani A, Pastrana DV, Fitzgerald DJ.
Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.
J. Biol. Chem. 284: 10243-53, 2009.
[Journal]
27)  Du X, Beers R, Fitzgerald DJ, Pastan I.
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
Cancer Res. 68: 6300-5, 2008.
[Journal]
28)  Pastrana DV, Yun CH, McKee ML, Fitzgerald DJ.
Mammalian cell expression of an active site mutant of Pseudomonas exotoxin disrupts LRP1 maturation.
J. Biomed. Sci. 15: 427-39, 2008.
[Journal]
29)  Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ.
Immunotoxin treatment of cancer.
Annu. Rev. Med. 58: 221-37, 2007.
[Journal]
30)  Pastrana DV, FitzGerald DJ.
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin.
Anal. Biochem. 353: 266-71, 2006.
[Journal]
31)  Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ.
Immunotoxin therapy of cancer.
Nat. Rev. Cancer. 6: 559-65, 2006.
[Journal]
32)  Hsieh JC, Tham DM, Feng W, Huang F, Embaie S, Liu K, Dean D, Hertle R, Fitzgerald DJ, Mrsny RJ.
An intranasal immunization strategy to impede pilin-mediated binding of P. aeruginosa to airway epithelial cells.
Infect Immun. 73: 7705-17, 2005.
[Journal]
33)  Pastrana DV, Hanson AJ, Knisely J, Bu G, Fitzgerald DJ.
LRP1B functions as a receptor for Pseudomonas exotoxin.
Biochim Biophys Acta. 1741: 234-9, 2005.
[Journal]
34)  Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I.
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies.
J Clin Oncol. 23: 6719-29, 2005.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.